Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Pinpoint Problem Missed by China's Broad Stimulus
45:54 - In today's "Morning Must Read," Bloomberg’s Vonnie Quinn recaps the op-ed pieces and analyst notes providing insight behind today's headlines on "Bloomberg Surveillance.” (Source: Bloomberg)
  • Sanders Closes the Gap With Clinton on Iowa
  • What You Need to Know: Fed, China, Stocks
  • Maersk Wins U.K Approval for Gas Field